Session Information

HomeProgramSession Information ▶ Virtual Industry Programs
Virtual Industry Programs

Enhance your educational experience during ATS 2020 Virtual by listening to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine. There are 10 programs that will be available on-demand on the ATS 2020 Virtual platform until November 10.

To access the industry program, please click on the title of the program below to be directed to the ATS 2020 Virtual platform. The platform is only accessible by registered attendees.

A New Direction in PAH: A Potential Therapy for Rebalancing BMPR2 Signaling

Sponsored by Acceleron Pharma
Open to all attendees
Topic: Pulmonary Arterial Hypertension (PAH)

Despite multiple treatment options, patients with PAH still face a devastating and progressive disease. This program will focus on the imbalances in BMPR2 and activin receptor signaling that may drive PAH progression. A new therapeutic approach that aims to rebalance this signaling will be discussed in the context of potential disease modification.


  • Vallerie McLaughlin, MD, University of Michigan, Ann Arbor

Clinical Overview of SUNOSI and a Patient Case Study

Sponsored by Jazz Pharmaceuticals
Open to U.S. attendees only
Topic: Obstructive Sleep Apnea (OSA)

Join your fellow healthcare professionals for an engaging presentation including:

  • The burden and mechanism of disease of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA)
  • An overview of the clinical efficacy and safety of SUNOSI
  • A clinical case to help identify patients who may be candidates for SUNOSI


  • Richard E. Friedenheim, MD, Medical Director, Abington Sleep Disorders Center, Abington Pulmonary and Critical Care Associates, Abington Hospital - Jefferson Health

ISABELA - how to execute the largest Phase 3 program in IPF to date

Sponsored by Gilead Sciences & Galapagos
Open to all attendees
Topic: Idiopathic Pulmonary Fibrosis (IPF)

The ISABELA clinical trial programe is planned to be the largest phase 3 programme performed in patients with IPF to date, globally recruiting 1,500 patients in a rare disease population. This presentation will showcase the innovative and agile ways in which Galapagos have responded to the needs of patients and investigators to ensure the successful execution of these trials.


  • Paul Ford, MD PhD, Galapagos

Nontuberculous Mycobacterial Lung Disease: Optimizing Diagnosis and Management to Improve Outcomes

A non-CME educational program sponsored by Vindico Medical Education and supported by a grant from Insmed Incorporated

Open to all attendees
Topic: Nontuberculous Mycobacteria (NTM)

Join us as our faculty review up-to-date knowledge of nontuberculous mycobacteria (NTM) epidemiology and pathogenesis and provide guidance on use of appropriate diagnostic criteria. We will also discuss evidence-based approaches to manage NTM pulmonary disease and strategies for applying the latest clinical data when selecting therapy for refractory disease.


  • Anne O'Donnell, MD, Professor of Medicine; Chief, Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center
  • Kevin Winthrop MD, MPH, Professor, Division of Infectious Diseases Schools of Medicine and Public Health, Oregon Health and Sciences University

Optimizing the Care of Patients with Progressive-Fibrosing Interstitial Lung Disease: Applying the Latest Data

A non-CME educational program sponsored by Vindico Medical Education and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Open to all attendees
Topic: Progressive Fibrosing - Interstitial Lung Disease (PF-ILD)

Join us for a non-CME virtual program to review the latest guidelines and evidence for diagnosing and treating progressive fibrosing interstitial lung disease (PF-ILD). This educational activity will emphasize the importance of treatment adherence and effective multidisciplinary approaches to improve the quality of care for your patients. We will discuss clinical cases focused on integrating optimal diagnostic and therapeutic approaches into practice.


  • Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital
  • Kevin R. Flaherty, MD, Professor of Medicine Division of Pulmonary/Critical Care Medicine Director, Michigan Medicine Interstitial Lung Disease Clinic, University of Michigan

Reclassifying risk of malignancy in indeterminate pulmonary nodules using the Nodify Lung™ testing strategy.

Sponsored by Biodesix, Inc.
Open to all attendees
Topic: Lung Cancer/Lung Disease

This program will provide an overview of the Nodify Lung testing strategy, discuss case studies using the Nodify CDT™ and Nodify XL2™ tests and share recent data published from the ORACLE clinical study and real-world clinical use.

Dr. Pritchett will discuss how the testing strategy helps identify patients with a higher risk of malignancy who may be considered for timely intervention and those with a lower risk of malignancy who may be considered for CT surveillance.


  • Michael Pritchett, DO, MPH, Director of Thoracic Oncology, Pulmonary and Critical Care Physician, President of the Society for Advanced Bronchology, Firsthealth of the Carolinas, and Pinehurst Medical Clinic

Severe Eosinophilic Asthma: Case Studies With a Targeted Treatment Approach

Sponsored by AstraZeneca
Open to all attendees
Topic: Asthma

You are cordially invited to view a pre-recorded program to learn about the clinical impact of a targeted biologic treatment option on exacerbations and lung function in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action, and safety profile data.


  • Donna Carstens, MD, Pulmonary Medicine, Sr. Medical Director, AstraZeneca

Type 2 Inflammation in Asthma, CRSwNP, NSAID-ERD, and COPD

Sponsored by Sanofi Genzyme and Regeneron
Open to all attendees
Topic: Asthma

Hear experts review Type 2 inflammation as an underlying disease process that contributes to frequently coexisting conditions. Our experts will review current literature on key cytokines or IL-4/IL-13, which contribute to the key components of Type 2 inflammation: allergic inflammation, eosinophilic inflammation, and epithelial barrier dysfunction. In addition, the implications of coexisting Type 2 inflammatory diseases, such as greater disease severity and worse disease control, will be reviewed.


  • William J. Calhoun MD, Professor of Internal Medicine, Pulmonary, Allergy, and Clinical Immunology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
  • Monica Kraft, MD, Professor, Medicine, Chair, Department of Medicine, UA Health Sciences Asthma and Airway Disease Research Center, Tuscon, AZ

Understanding the Role of Type 2 Inflammation in Airway Diseases: Interconnections and Interdisciplinary Considerations

Sponsored by Regeneron and Sanofi Genzyme
Will be available on-demand soon | Open to all attendees
Topic: Asthma

While inflammatory airway diseases are heterogeneous, Type 2 inflammation is a common underlying pathophysiology in many affected patients. In particular asthma and CRSwNP, two airway diseases that are predominantly driven by Type 2 inflammation, pose a substantial burden to patients, which is further increased when these diseases coexist. An understanding of Type 2 inflammation in asthma, a lower airway disease and CRSwNP, an upper airway disease, and the interactions between them, is imperative to reducing disease burden and improving control. This program will review the importance of Type 2 inflammation in asthma and CRSwNP, including their shared pathophysiology, the role of key Type 2 cytokines and why management of these diseases must involve interdisciplinary approaches and considerations.


  • William W. Busse, MD, Professor of Medicine, Allergy,Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin
  • Kenneth R. Chapman, MD, MSc, Professor of Medicine, Director of the Asthma and Airway Centre, University of Toronto, University Health Network, Toronto, Canada
  • Jivianne T. Lee, MD, Associate Professor, Rhinology & Endoscopic Skull Base Surgery, Department of Head & Neck Surgery, UCLA David Geffen School of Medicine, Los Angeles, California

Ventilatory Support during COVID-19

Sponsored by Philips
Open to all attendees
Topic: COVID-19

This presentation will present guidelines and clinical observations for respiratory management of COVID-19 with a focus on current aspects of ventilation.


  • Adam Seiver, MD, Chief of Medical Affairs, Philips